Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc.
source https://www.pharmatutor.org/pharma-news/2020/roche-initiates-phase-iii-clinical-trial-of-actemra-roactemra-plus-remdesivir-in-hospitalised-patients-with-severe-covid-19-pneumonia
No comments:
Post a Comment